Tomato Consumption and High Density Lipoprotein-cholesterol
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
- This is a randomized, open-label, single blind, clinical trial
- The study evaluated the effect of tomato consumption in serum HDL-cholesterol levels.
- The hypothesis was that two daily tomatoes during one month will increase the HDL-c levels.
- Since a placebo of tomatoes cannot be done, the control group will receive same proportion of cucumber because 1) it was not possible to have a tomato placebo; 2) cucumber does not have any lycopene; 3) both can be prepared similarly; and 4) the required quantity can be measured in the same way.
- The intervention was during 1 month and was assigned by randomization.
- Personnel who did the clinical and biochemical evaluation were blinded for the intervention.
- Lipid profile was measured before and after the intervention.
- Confounding factors such as daily physical activity, diet, consumption of fish or alcoholic beverages, smoking status were considered during statistical analyses.
| Condition | Intervention |
|---|---|
|
Hypoalphalipoproteinemia |
Dietary Supplement: Tomato consumption Dietary Supplement: Cucumber consumption |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Effect of Tomato Consumption on Serum High Density Lipoprotein-cholesterol Levels. A Randomized, Open-label, Single Blind, Clinical Trial |
- High Density Lipoprotein Cholesterol (HDL-c) [ Time Frame: Baseline and after one month ] [ Designated as safety issue: No ]To evaluate the effect of two daily tomatoes consumption on HDL-c levels.
| Enrollment: | 50 |
| Study Start Date: | March 2009 |
| Study Completion Date: | December 2011 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Tomato consumption
Daily consumption of 300g of uncooked roma tomatoes during one month.
|
Dietary Supplement: Tomato consumption
Daily consumption of 300g of uncooked roma tomatoes during one month.
|
|
Placebo Comparator: Cucumber consumption
Daily consumption of 300g of cucumber.
|
Dietary Supplement: Cucumber consumption
Daily consumption of 300g of cucumber.
|
Detailed Description:
Cardiovascular disease (CVD) is a main cause of death worldwide (1) and there are well recognized risk factors associated with its development. Low high density lipoprotein-cholesterol (HDL-c) rank among the most common lipid abnormalities associated with CVD (2). Low HDL-c is currently defined as an HDL-c value below 40 mg/dL for men and below 50 mg/dL for women (3). Factors related with low HDL-c are cigarette smoking (4), high triglycerides (5), sedentary lifestyle (6), and insulin resistance (7). Non-pharmacologic strategies to increase HDL-c concentration are increasing alcohol (8) and fish consumption (9), weight reduction (3), increment in physical activity (10), and smoking cessation (8). Some of these strategies are not applicable or hard to implement in individuals affected with low HDL-c. Moreover, in low-income countries, these interventions could be costly for the general population. Vegetables consumption could be a more affordable and accessible option to treat low HDL-c. Epidemiologic evidence indicates that high consumption of vegetables reduces the risk of cardiovascular disease (11) and particular attention has received tomato-based products. Growing evidence from several epidemiological studies has indicated that lycopene, the major carotenoid in tomato (12), might be more important than other carotenoids in preventing atherosclerosis and CVD (13, 14). The consumption of more than 7 servings per week of tomato-based products has been associated with a 30% reduction in the relative risk of CVD (15). Such potential benefits to vascular health from a tomato-rich diet could be related to low arterial intimal wall thickness (13, 16), reduction of LDL cholesterol levels (17), and inverse correlation with markers of inflammation and vascular endothelial dysfunction (18). However, HDL-c levels could also be positively influenced by tomato consumption. In a pilot study we found that tomato juice consumption did not increase HDL-c after one month (unpublished data), this finding also was recently reported by another group (19). In contrast, other study showed that daily consumption of 300g of uncooked tomatoes, during one month significantly increased HDL-c levels by 15.2% (20). However, this study was not controlled, not blinded, and neither randomized. Roma tomatoes consumption could be an accessible intervention to improve HDL-c levels; however, a longitudinal clinical trial is necessary to evaluate this association. Therefore, we performed a randomized, open-label, single blind, clinical trial to specifically evaluate if consumption of two uncooked tomatoes per day (14 servings/week) during one month could produce a favorable effect on HDL-c.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males with HDL-c less than 40 mg/dl
- Females with HDL-c less than 50 mg/dl
- Age between 18 to 65 years old
- Acceptance for participation with signed informed consent
Exclusion Criteria:
Previous diagnosis of:
- Diabetes,
- Hypertension,
- Kidney, liver or heart insufficiency,
- Hyperuricemia,
- Hyperandrogenic anovulation,
- Thyroid dysfunction (hypo or hyperthyroidism),
- Any difficulty to swallow appropriately, or
- Hospitalization in the previous six months.
Additionally, those subjects under current treatment with fibrates, statins, nicotinic acid, steroids, allopurinol, hormone replacement therapy (testosterone, estrogens or progesterone), metformin, other oral hypoglycemic agents, insulin, sibutramine, or orlistat treatment and those with daily consumption of any non-steroidal anti-inflammatory drug were also excluded.
Contacts and Locations| Mexico | |
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | |
| Mexico, Tlalpan, Mexico, 14000 | |
| Principal Investigator: | Francisco J Gomez-Perez, MD, FACE | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
More Information
Publications:
| Responsible Party: | Daniel Cuevas-Ramos, MD, PhD, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| ClinicalTrials.gov Identifier: | NCT01342666 History of Changes |
| Other Study ID Numbers: | REF2039 |
| Study First Received: | April 26, 2011 |
| Results First Received: | January 10, 2013 |
| Last Updated: | February 23, 2013 |
| Health Authority: | Mexico: Ethics Committee |
Keywords provided by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran:
|
High density lipoprotein cholesterol Tomato Lycopene Hypoalphalipoproteinemia Dyslipidemia |
Additional relevant MeSH terms:
|
Hypoalphalipoproteinemias Hypolipoproteinemias Lipid Metabolism, Inborn Errors Metabolism, Inborn Errors |
Genetic Diseases, Inborn Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on May 23, 2013